Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
News|Articles|November 8, 2018
Ardena Moves to Expanded Headquarters in Belgium
Author(s)Pharmaceutical Technology Editors
Ardena has moved into its expanded headquarters, located in Gent, Belgium, as a result of continued growth.
Advertisement
Ardena, a contract development and manufacturing organization (CDMO), has moved to expanded headquarters in Gent, Belgium, as a result of sustained growth, it has revealed in a Nov. 8, 2018
Now operating across six sites, located in Belgium, the Netherlands, Sweden, and Latvia, the company has increased its employees from 40 to 250 and seen an increase in organic growth of more than 20% per year, which it states is a result of its merger and acquisition strategy.
"After several acquisitions and an ongoing growth period, we are firmly on track to reach our €35 million (approximately $40 million) sales target for 2018 as part of our wider strategy to become a leading integrated drug development company," said Harry Christiaens, CEO at Ardena in a
Inauguration of the new HQ took place on Oct. 25, 2018.
Source:
Advertisement
Related to this article
Andrew Parker, PhD, executive drug development consultant, Quotient Sciences, explains how AI is integrated into pharmaceutical development.
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Advertisement
Advertisement